Copyright
©The Author(s) 2022.
World J Diabetes. Aug 15, 2022; 13(8): 587-599
Published online Aug 15, 2022. doi: 10.4239/wjd.v13.i8.587
Published online Aug 15, 2022. doi: 10.4239/wjd.v13.i8.587
Stage | Estimated period | Characteristics | GFR | BP | Biomarker-albuminuria | Biomarker UACR mg/mmoL |
1 = hyperfiltration | From diabetes onset to 5 yr | Glomerular hyperfiltration and hypertrophy. No ultrastructure abnormality. A 20% increase in renal size. ↑Renal plasma flow | N/increased | N | Normoalbuminuria < 30 mg/g | < 2 |
2 = silent | From 2 yr after onset | Mild GBM thickening and interstitial expansion | N | N | Normoalbuminuria < 30 mg/g | < 3 |
3 = incipient | 5–10 yr after onset | More significant changes vs stage 2. Moderate tubular and GBM thickening and variable focal mesangial sclerosis | GFR–N or mild decreased | Increasing BP; +/- hypertension | Microalbuminuria appears Albuminuria 30-300 mg/g | 2-20 |
4 = overt | 10-15 yr after onset | Marked GBM thickening and variable focal mesangial sclerosis | GFR-decreased < 60 mL/min/1.73 | BP↑ | Macroalbuminuria > 300 mg/g | > 20 |
5 = uremic | Diffuse glomerulosclerosis, ESRD | GFR-marked decreased < 15 mL/min/1.73 m2 | BP↑ | Decreasing albuminuria |
- Citation: Muntean C, Starcea IM, Banescu C. Diabetic kidney disease in pediatric patients: A current review. World J Diabetes 2022; 13(8): 587-599
- URL: https://www.wjgnet.com/1948-9358/full/v13/i8/587.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i8.587